Alkermes plc (Alkermes) recently announced the next evolution of the Alkermes Pathways Research Awards program, an initiative designed to support the next generation of researchers who are working on the front lines to advance understanding and awareness of central nervous system (CNS) disorders. The program will continue to support projects focused on helping those living with addiction disorder, and is expanding to include projects dedicated to helping people living with schizophrenia. The current application cycle will run through July 31, 2019.
Now open to early-career investigators committed to advancing research in addiction disorder and/or schizophrenia, the second annual Pathways program grants will provide funding for up to eight research projects, with individual grant amounts of up to $100,000 per project. Alkermes has reserved four awards for research focused on addiction disorder, and four awards for research focused on schizophrenia.
Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system diseases. The organization has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction disorder, and multiple sclerosis.
This was reported by Alkermes plc on April 3, 2019.
Contact Information: Alkermes plc, 852 Winter Street, Waltham, Massachusetts 02451; (781) 609-6000; Website: www.alkermes.com